The Antioxidant Effect of Routine Vascular Therapy for Normal Tension Glaucoma Patients

This study has been withdrawn prior to enrollment.
(investigator withdrew)
Sponsor:
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT00465348
First received: April 24, 2007
Last updated: October 24, 2012
Last verified: October 2012
  Purpose

To quantify oxidative stress in circulating leukocytes of normal tension glaucoma patients, prior to and one month after routine vascular therapy.


Condition
Primary Open Angle Glaucoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Antioxidant Effect of Routine Vascular Therapy for Normal Tension Glaucoma Patients

Resource links provided by NLM:


Further study details as provided by University Hospital, Basel, Switzerland:

Biospecimen Retention:   None Retained

plasma


Enrollment: 0
Study Start Date: June 2009
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Detailed Description:

There are two accepted medical modalities for glaucoma treatment. The first, is a local application of an intraocular pressure (IOP) lowering drug. The second, is the application of systemic drugs to improve vascular regulation. In the present study we would like to investigate whether this systemic form of treatment, in addition to improving blood flow, also reduces systemic oxidative stress.

Vascular dysregulation is one of the major risk factors for glaucoma, in particular for normal tension glaucoma (NTG). In glaucoma patients blood flow is, on average, reduced not only in the eye but also in various other organs of the body, for example in the fingers. Such a systemic dysregulation leads to disturbed autoregulation and thereby to an unstable oxygen supply in the eye.This, in turn, leads to the formation of reactive oxygen species (ROS). These ROS are capable of damaging cells such as white blood cells; this damage, however, is reversible as nature has provided us with mechanisms to repair this damage. This reversible damage brought about by ROS, which is constantly being repaired in our body, is an indication for oxidative stress. Oxidative stress plays an important role in the pathogenesis of glaucoma.

The indications for oxidative stress can be quantified in our laboratory by the method of comet assay also known as single cell gel electrophoresis.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

primary open-angle glaucoma patients

Criteria

Inclusion Criteria:

For NTG patients:

  • A mean untreated intraocular pressure consistently equal to or below 21mmHg or median intraocular pressure equal to or below 20mmHg on diurnal testing (at least three measurements) with no single measurement greater than 24mmHg
  • Open drainage angles on gonioscopy
  • Typical optic disc damage with glaucomatous cupping and thinning of neuroretinal rim
  • Visual field defect congruent to glaucomatous disc alteration
  • No other pathological findings upon slit-lamp examination and indirect fundoscopy
  • Vasospastic propensity will be assumed if a clear history of frequent cold hands (answering yes to the questions:" Do you always have cold hands, even during the summer time?" and "Do other people tell you that you have cold hands?") is reported.

For healthy subjects:

  • An intraocular pressure < 20 mmHg
  • No history of ocular or systemic disease
  • No history of chronic or current systemic or topical medication, or of drug or alcohol abuse
  • Normal blood pressure (100-140/60-90mm Hg)
  • Best corrected visual acuity above 20/32 in both eyes
  • No pathological findings upon slit-lamp examination and indirect fundoscopy

Exclusion Criteria:

EXCLUSION CRITERIA:

  • Iridocorneal angle extremely narrow with complete or partial closure as determined by gonioscopy
  • Pigmentary dispersion or pseudoexfoliation
  • Evidence for any secondary cause for a glaucomatous optic neuropathy (trauma, steroids, uveitis)
  • History of chronic or recurrent severe inflammatory eye disease (eg. scleritis, uveitis) or clinically significant or progressive retinal disease (eg. diabetic retinopathy)
  • History of ocular trauma or intraocular surgery within the past 6 months
  • History of systemic infection or inflammation within the past 3 months
  • Need for any concomitant medications that may interfere with the evaluation of leukocytes (eg: steroids, immunosuppressives)
  • Patients with a significant history and /or active alcohol or drug abuse (significant is defined as that which may influence results of the study)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00465348

Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Study Director: Selim Orgül, MD University Hospital Basel, Eye Clinic
  More Information

Publications:
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00465348     History of Changes
Other Study ID Numbers: 085-Mom-2007
Study First Received: April 24, 2007
Last Updated: October 24, 2012
Health Authority: Switzerland: Swissmedic

Keywords provided by University Hospital, Basel, Switzerland:
normal tension glaucoma
vascular dysregulation

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Low Tension Glaucoma
Eye Diseases
Ocular Hypertension
Optic Nerve Diseases
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents

ClinicalTrials.gov processed this record on October 23, 2014